carbapenems has been researched along with isoniazid in 1 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (isoniazid) | Trials (isoniazid) | Recent Studies (post-2010) (isoniazid) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 21,815 | 960 | 4,493 |
| Protein | Taxonomy | carbapenems (IC50) | isoniazid (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 4.85 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 8.29 | |
| Putative FAD-containing monooxygenase MymA | Mycobacterium tuberculosis H37Rv | 4.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caminero, JA; Migliori, GB; Piubello, A; Scardigli, A | 1 |
1 other study(ies) available for carbapenems and isoniazid
| Article | Year |
|---|---|
Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
Topics: Aminosalicylic Acid; Antitubercular Agents; Carbapenems; Clofazimine; Communicable Disease Control; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Infectious Disease Medicine; Isoniazid; Linezolid; Mycobacterium tuberculosis; Treatment Outcome; Tuberculosis, Multidrug-Resistant; World Health Organization | 2017 |